ANTHONY MAIDA - 31 Mar 2021 Form 4 Insider Report for Oncotelic Therapeutics, Inc. (OTLC)

Role
CHIEF CLINICAL OFFICER, Director
Signature
/s/ Anthony Maida
Issuer symbol
OTLC
Transactions as of
31 Mar 2021
Transactions value $
$0
Form type
4
Filing time
16 Jul 2021, 17:39:03 UTC
Next filing
08 Sep 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction OTLC Common Stock Conversion of derivative security +939K +472.47% 1.14M 31 Mar 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OTLC Series A Convertible Preferred Stock Conversion of derivative security -938 -100% 0 31 Mar 2021 Common Stock 939K Direct F1, F2
transaction OTLC Stock Options Award $0 +400K $0.00 400K 08 Jul 2021 Common Stock 400K $0.16 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.
F2 Shares of the Series A Convertible Preferred Stock does not expire.
F3 Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.